WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the ...

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) today and set a price target of $10.00. The company’s shares closed ...

Get news and updates about your favorite shows, plus 3 free credits to watch locked content.

Wiggins (Achilles) has been ruled out for Tuesday's game against the Kings. Wiggins will miss Tuesday's contest due to left Achilles tendinitis, and his next chance to play will come Thursday ...

Gordon (calf/ankle) has been ruled out for Monday's game against the Bulls. Gordon will miss his sixth outing during March due to right calf injury management and a left ankle sprain. With the 29 ...

MLB fans were treated to a special season in 2024, with guys like Aaron Judge, Shohei Ohtani, and Tarik Skubal going above and beyond. They kept fans on the edge of their seats all season long ...

Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...

(MENAFN- GlobeNewsWire - Nasdaq) – Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab ...

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first ...

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the ...